MedPath

Response of Haemodialysis Patients to BNT162b2 mRNA Cov-19 Vaccine

Completed
Conditions
COVID-19 Vaccines
Hemodialysis Complication
Registration Number
NCT04881396
Lead Sponsor
Hospices Civils de Lyon
Brief Summary

Vaccination against SARS-Cov2 is a necessity for haemodialysis patients because difficulties to maintain a self-isolation (leading to a higher contamination than general population) and an increase of mortality in case of contamination (more than 20% of mortality in this population). However, vaccine efficiency is known to be decreased in haemodialysis patients. This lead critical the rapid description of immunogenicity of anti SARS-Cov2 vaccine in haemodialysis patients.

The aim of this study is to describe the immunogenicity of the BTN162b2 SARS-Cov2 vaccine in haemodialysis patients.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
99
Inclusion Criteria
  • Medical prescription of BTN162b2 mRNA Cov-19 vaccine
  • Treatment by chronic (>1 month) haemodialysis
Exclusion Criteria
  • Non-recommended vaccination scheme
  • Refusal to consent

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Seroconversion rate after vaccination with BTN162b2 mRNA cov-19 vaccineThe seroconversion rate is evaluated at Day 7-Day 14 after the second dose.

IgG anti SARS-Cov2 spike protein will be evaluated by ELISA at Day 0 (at the initiation of vaccination) anti Day 7 - Day 14 after the second dose (peak of response).

The seroconversion is defined by an 4 fold increase of IgG anti SARS-Cov2 spike protein titer between Day 0 and Day 7 - Day 14 after second dose.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (2)

Department of Nephrology, Hopital Edouard Herriot

🇫🇷

Lyon, France

Department of Nephrology, Centre Hospitalier Lyon Sud

🇫🇷

Pierre Bénite, France

Department of Nephrology, Hopital Edouard Herriot
🇫🇷Lyon, France

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.